NTCELL Phase I/IIa study meets endpoints
15 June 2015 | By Victoria White
A Phase I/IIa study of NTCELL, an regenerative cell therapy being studied as a disease-modifying agent in Parkinson’s disease, has met its endpoints...
List view / Grid view
News
AstraZeneca announces Phase III results for lesinurad in combination with febuxostat in patients with tophaceous gout
15 June 2015 | By Victoria White
AstraZeneca presented results from its Phase III trial investigating lesinurad in combination with febuxostat in patients with tophaceous gout at EULAR 2015...
Positive results from Phase 3 study evaluating Cimzia in DMARD-naïve rheumatoid arthritis patients
15 June 2015 | By Victoria White
UCB has announced data from a Phase 3 study that showed the substantial benefits, at 52 weeks, of adding Cimzia to optimised methotrexate treatment...
Chickenpox vaccine can be effective and safe even in children with paediatric rheumatic disease
12 June 2015 | By Victoria White
Results from a new study show that the chickenpox vaccine can be safe even in children with rheumatic disease receiving immunosuppression treatment...
Updated results from Celgene’s FIRST Study of REVLIMID presented at European Haematology Association congress
12 June 2015 | By
Celgene International has announced updated results of its pivotal Phase III FIRST trial of REVLIMID at the European Haematology Association annual congress...
Arzerra improved median progression-free survival by 54% in patients with relapsed chronic lymphocytic leukaemia
12 June 2015 | By Victoria White
Novartis has presented promising data from the Phase III COMPLEMENT 2 study of Arzerra in patients with replapsed chronic lymphocytic leukaemia...
Novartis’ Xolair improves quality of life by 78% for chronic spontaneous urticaria patients
12 June 2015 | By Victoria White
New analyses from pivotal Phase III studies show Xolair helps patients with Chronic Spontaneous Urticaria achieve improvements in quality of life measures...
Phase 3 study evaluating Pristiq in paediatric patients with major depressive disorder fails to meet its primary objective
12 June 2015 | By Victoria White
Top line results from a Phase 3 study evaluating Pristiq in paediatric patients with Major Depressive Disorder (MDD) have been announced...
ORYX’s oncolytic parvovirus H1 successfully completes Phase I/IIa trial to treat glioblastoma multiforme
12 June 2015 | By Victoria White
ORYX's Phase I/IIa trial assessing oncolytic parvovirus H1 as a treatment for patients with glioblastoma multiforme has been successfully completed...
Capita Healthcare Decisions supports national online healthcare service in Australia
11 June 2015 | By Victoria White
Capita Healthcare Decisions has won a contract with Healthdirect Australia to help people check their symptoms online and receive healthcare advice...
First patient in Singapore treated with BTG’s TheraSphere radioembolization therapy
11 June 2015 | By Victoria White
The first patient in Singapore has been treated with TheraSphere radioembolization therapy- a treatment for primary liver cancer and metastatic bowel cancer...
Celyad completes 30-day safety follow-up of first patient in NKG2D Phase I trial
11 June 2015 | By Victoria White
Celyad has completed the 30-day safety follow-up of the first patient enrolled in a Phase I clinical trial evaluating the safety of NKG2D CAR T-cell therapy..
Merck Serono wins two Red Dot Awards for its fertility pens
11 June 2015 | By Victoria White
Merck Serono has announced that the product design of its fertility pens won over the 38-member jury of the Red Dot Award: Product Design 2015...
Janssen to present 17 abstracts in ankylosing spondylitis, rheumatoid arthritis, psoriatic arthritis and psoriasis at EULAR
11 June 2015 | By Victoria White
Seventeen Janssen Immunology abstracts in ankylosing spondylitis, rheumatoid arthritis, psoriatic arthritis and psoriasis, will be presented at EULAR...
Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit ovulation after just 10 days
11 June 2015 | By Victoria White
The results of a study presented at EULAR 2015 show that NSAIDs, such as diclofenac, significantly inhibit ovulation in women with mild musculoskeletal pain...
